Is measuring endothelial function a good idea for prediction of coronary heart disease complications?

European Heart Journal

Volumn 23, Issue 22, 2002, Pages 1728-1730

  Koenig, W ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8A; C REACTIVE PROTEIN; ENOXAPARIN; HEPARIN; HIRUDIN; THROMBIN; VON WILLEBRAND FACTOR;

ARTERY ENDOTHELIUM; ATHEROGENESIS; EDITORIAL; ENDOTHELIUM CELL; HUMAN; ISCHEMIC HEART DISEASE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOGENICITY; VASOCONSTRICTION; VASODILATATION;

CELL ADHESION MOLECULES; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; RISK FACTORS;

EID: 0036845571     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2002.3310     Document Type: Editorial

References (15)

1. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993; 22(Suppl 4): S1-S14.
2. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999; 340: 115-26.
3. Luster AD. Chemokines - Chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-45.
4. Vita JA, Treasure CB, Nabel EG et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 491-7.
5. Al Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
6. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
7. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. Am J Pathol 2000; 190: 244-54.
8. Whincup PH, Danesh J, Walker M et al. Von Willebrand factor and coronary heart disease: Prospective study and meta-analysis. Eur Heart J 2002; 23: 1764-70.
9. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. Von Willebrand factor is an acute phase reactant in man. Throm Res 1989; 53: 387-94.
10. Mannucci PM. Von Willebrand factor: A marker of endothelial damage? Arterioscler Thromb Vasc Biol 1998; 18: 1359-62.
11. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: Does it exist? Br J Haematol 1995; 90: 234-41.
12. Jager A, van Hinsbergh VWM, Kostense PJ et al. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. The Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 3071-8.
13. Montalescot G, Philippe F, Ankri A et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin. Circulation 1998; 98: 287-9.
14. Montalescot G, Collet JP, Lison L et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110-4.
15. Malik I, Danesh J, Whincup P et al. Soluble adhesion molecules and prediction of coronary heart disease: A prospective study and meta-analysis. Lancet 2001; 358: 971-5.